We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Liquid Biopsy Predicts Immunotherapy Response and Toxicity in Advanced Lung Cancer Patients

By LabMedica International staff writers
Posted on 13 Dec 2023
Print article
Image: Liquid biopsy to study genetic material shed into bloodstream helps predict response to immunotherapy (Photo courtesy of Valsamo `Elsa` Anagnostou using DALL-E)
Image: Liquid biopsy to study genetic material shed into bloodstream helps predict response to immunotherapy (Photo courtesy of Valsamo `Elsa` Anagnostou using DALL-E)

Immunotherapy has been a game-changer in treating lung cancer patients, yet assessing its effectiveness remains a challenge. The absence of reliable biomarkers means reliance on imaging and patient symptoms to gauge clinical responses. Now, new noninvasive tests offer clinicians a way to evaluate treatment responses and foresee potential side effects at an early stage, allowing for timely adjustments in therapeutic approaches.

Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) have explored the use of a "liquid biopsy" to analyze genetic material from tumors that enter the bloodstream along with immune cells. This approach could enable clinicians to predict which patients with advanced lung cancers are responding to immunotherapies and identify those who might experience immune-related side effects later on. In a study of 30 patients undergoing immunotherapy for metastatic non-small cell lung cancers, the team monitored changes in circulating tumor DNA (ctDNA). They found that molecular responses, indicated by the reduction of tumor genetic material in the bloodstream, were closely linked with progression-free and overall survival rates.

Additionally, the research included serial blood tests that identified an increase in T cells, the immune cells known for recognizing and attacking foreign entities on tumor cells. This was particularly evident in patients who developed immune-related adverse events, like lung tissue inflammation, up to five months before clinical symptoms appeared. This finding was corroborated in a separate group of 49 patients with advanced lung cancers. The liquid biopsy proved beneficial in understanding the clinical outcomes of patients who appeared to have stable disease on imaging.

“All of the patients who appeared to have stable disease on imaging tests had very different DNA molecular response patterns that helped predict their overall clinical outcomes,” said senior study author Valsamo “Elsa” Anagnostou, M.D., Ph.D. “This is a particular subset of patients for whom we may want to intervene, and use liquid biopsies to guide therapeutic decision-making, as ctDNA can rapidly and accurately capture the amount of cancer present.”

Related Links:
Johns Hopkins Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article



view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more


view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more


view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.